Triple Antiplatelet Therapy with Cilostazol and Favorable Early Clinical Outcomes after Acute Myocardial Infarction Compared to Dual Antiplatelet Therapy with Standard or Potent P2Y12 Inhibitors
Current guidelines for the management of acute myocardial infarction (AMI) recommend potent P2Y12 inhibitors rather than clopidogrel to prevent ischemic events. However, their ischemic benefits are offset by an increased major bleeding risk. We compared the efficacy and safety of triple antiplatelet...
Main Authors: | Sungwook Byun, Su Nam Lee, Sungmin Lim, Eun Ho Choo, Ik Jun Choi, Chan Joon Kim, Donggyu Moon, Mahn-Won Park, Chul Soo Park, Youngkeun Ahn, Myung-Ho Jeong, Kiyuk Chang |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-11-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/11/22/6856 |
Similar Items
-
Tailoring antiplatelet therapy in older patients with coronary artery disease
by: Mila Kovacevic, et al.
Published: (2023-12-01) -
TIMELINE FOR THE DOUBLE ANTIPLATELET THERAPY. FACTS AND SUGGESTIONS
by: O. L. Barbarash, et al.
Published: (2016-02-01) -
Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective
by: Gregorio Tersalvi, et al.
Published: (2020-07-01) -
Antiplatelet Therapy Aims and Strategies in Asian Patients with Acute Coronary Syndrome or Stable Coronary Artery Disease
by: Chor-Cheung Tam, et al.
Published: (2022-12-01) -
Recurrent Non-Variceal Upper Gastrointestinal Bleeding among Patients Receiving Dual Antiplatelet Therapy
by: Ah Young Yoo, et al.
Published: (2023-11-01)